Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Protein biomarkers have become essential tools in the diagnosis, prognosis, and treatment of breast cancer. In breast cancer, specific proteins are associated with various disease states, including tumor progression, metastasis, and response to treatment. Alfa Cytology is committed to advancing the use of protein biomarkers in breast cancer diagnostics, offering a comprehensive suite of services that encompass biomarker discovery and validation.
Biomarkers are indicators that objectively measure and evaluate normal biological processes, pathological processes, or responses to drug interventions. When organisms are damaged, biomarkers play an important early warning role. Proteins can directly control and regulate most of the physiological functions of the human body. The proteome is very dynamic and changes dramatically in response to biological signals, environmental conditions, and other external stimuli. Given this pivotal role, the protein could serve as an important biomarker for breast cancer (BC). BC is the most common malignant tumor worldwide. Currently, BC diagnosis methods are mainly through imaging, histopathology, hormone receptor, and genetic testing. However, some of these methods have the problem of low accuracy. Therefore, it is of great value to develop new technologies for early and high-precision diagnosis.
Fig.1 Application of proteomics-based identification of dysregulated pathways and biomarkers discovery in BC (Neagu AN, et al., 2023)
Alfa Cytology has extensive experience in BC basic research and biomarker development. The detection of protein biomarkers provides patients with important clinical information and provides guidance for diagnosis, prognosis, and pharmacodynamics. Currently, the body fluid samples (matrix) used in the detection of common protein biomarkers include serum, plasma (containing different types of anticoagulants), urine, cerebrospinal fluid, cell lysate, stool, etc. With advanced technology and a professional team, we can provide BC diagnostic development services, including protein biomarkers development for BC diagnosis. We have a professional protein biomarkers detection platform. For free protein biomarkers detection platforms, there are ELISA, MSD, SIMOA, Luminex, Ella, etc. For non-free protein biomarkers, detection platforms include flow cytometry, fluorescence microscopy, laser confocal microscopy, etc. Our services include,
Alfa Cytology is a leading global CRO company dedicated to assisting our clients in the discovery and validation of proteins as BC diagnostic biomarkers. Early detection of BC is important to improve prognosis and survival. Protein biomarkers are measurable molecules that have prognostic value for patients and can be used to diagnose the disease, or indicate the severity of the disease, and thus serve as diagnostic indicators for BC. If you are interested in learning more about our BC diagnostic development services, please feel free to contact us. Our professional and patient staff will get in touch with you as soon as possible.
Reference